TEL
AVIV, Israel,
Feb. 7, 2019 /PRNewswire/
-- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage
biopharmaceutical company focused on oncology and immunology, today
announced that it has closed its previously announced underwritten
public offering of 28,000,000 American Depositary Shares ("ADSs"),
each representing one of its ordinary shares, and warrants to
purchase 28,000,000 ADSs, at a public offering price of
$0.55 per ADS and accompanying
warrant. The warrants are exercisable immediately, expire five
years from the date of issuance and have an exercise price of
$0.75 per ADS. The gross proceeds of
the offering were $15.4 million,
before deducting underwriting discounts and commissions and
offering expenses payable by BioLineRx, and excluding the exercise
of any warrants. All of the securities in the offering were sold by
BioLineRx. BioLineRx anticipates using the net proceeds
from the offering for general corporate purposes, which may
include, but are not limited to, working capital and funding
clinical trials.
Oppenheimer & Co. Inc. acted as sole book-running manager
for the offering. Maxim Group LLC acted as co-manager for the
offering.
The securities described above were issued pursuant to a shelf
registration statement (File No. 333-222332) that was previously
filed with, and declared effective by, the Securities and Exchange
Commission ("SEC"). A final prospectus supplement related to the
offering has been filed with the SEC and is available on the SEC's
website located at www.sec.gov. Copies of the final prospectus
supplement may also be obtained from Oppenheimer & Co. Inc., 85
Broad St., 26th Floor, New York, New
York 10004, Attention: Syndicate Prospectus Department, or
by telephone: (212) 667-8055 or by email:
EquityProspectus@opco.com.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About BioLineRx
BioLineRx is a clinical-stage biopharmaceutical company focused
on oncology. The Company in-licenses novel compounds, develops them
through pre-clinical and/or clinical stages, and then partners with
pharmaceutical companies for advanced clinical development and/or
commercialization.
BioLineRx's leading therapeutic candidates are: BL-8040, a
cancer therapy platform, which has successfully completed a Phase
2a study for relapsed/refractory acute myeloid leukemia ("AML") and
is in the midst of a Phase 2b study
as an AML consolidation treatment and has initiated a Phase 3 study
in stem cell mobilization for autologous transplantation; and
AGI-134, an immunotherapy treatment in development for multiple
solid tumors, which has recently initiated a Phase 1/2a study. In
addition, BioLineRx has a strategic collaboration with Novartis for
the co-development of selected Israeli-sourced novel drug
candidates; a collaboration agreement with MSD (known as Merck in
the United States and Canada), on the basis of which the Company is
conducting a Phase 2a study in pancreatic cancer using the
combination of BL-8040 and KEYTRUDA® (pembrolizumab),
and a collaboration agreement with Genentech Inc., a member of the
Roche Group, to investigate the combination of BL-8040 and
Genentech's atezolizumab in several Phase 1b/2 studies for multiple solid tumor indications
and AML.
Various statements in this release concerning BioLineRx's
future expectations constitute "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements include words such as "may," "expects,"
"anticipates," "believes," and "intends," and describe opinions
about future events. These forward-looking statements involve known
and unknown risks and uncertainties that may cause the actual
results, performance or achievements of BioLineRx to be materially
different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Some of
these risks are: changes in relationships with collaborators; the
impact of competitive products and technological changes; risks
relating to the development of new products; and the ability to
implement technological improvements. These and other factors are
more fully discussed in the "Risk Factors" section of BioLineRx's
most recent annual report on Form 20-F filed with the Securities
and Exchange Commission on March 6,
2018 and BioLineRx's other filings with the Securities and
Exchange Commission. In addition, any forward-looking statements
represent BioLineRx's views only as of the date of this release and
should not be relied upon as representing its views as of any
subsequent date. BioLineRx does not assume any obligation to update
any forward-looking statements unless required by law.